Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. by Berruti, A et al.
Berruti et al. BMC Cancer 2014, 14:184
http://www.biomedcentral.com/1471-2407/14/184RESEARCH ARTICLE Open AccessBevacizumab plus octreotide and metronomic
capecitabine in patients with metastatic
well-to-moderately differentiated neuroendocrine
tumors: the xelbevoct study
Alfredo Berruti1*, Nicola Fazio2, Anna Ferrero3, Maria Pia Brizzi3, Marco Volante4, Elisabetta Nobili5, Lucia Tozzi6,
Lisa Bodei3, Mirella Torta3, Antonio D’Avolio7, Adriano Massimiliano Priola8, Nadia Birocco9, Vito Amoroso1,
Guido Biasco5, Mauro Papotti4 and Luigi Dogliotti3Abstract
Background: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic
well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). Ancillary studies evaluated hypertension,
proteinuria, and vascular endothelial growth factor (VEGF) polymorphisms in predicting progression-free survival (PFS)
and the predictive role of serum vitamin D in progression-free survival and proteinuria onset.
Methods: This prospective phase 2 study included 45 patients with WMD-NEN arising from various primary sites. The
treatment regimen was octreotide long-acting release (LAR), 20 mg monthly, metronomic capecitabine, 2000 mg/daily,
and intravenous bevacizumab, 5 mg/kg every 2 weeks, without interruption for 9 months. Bevacizumab was continued
until disease progression.
Results: Partial response was obtained in 8 patients (17.8%, 95% confidence interval [CI], 6.4%-28.2%); tumor response
was more frequent in pancreatic than in non-pancreatic malignancies. The median PFS was 14.9 months; median
overall survival was not attained. Biochemical and symptomatic responses were observed in 52.9% and 82.3% of cases,
respectively. The treatment was well tolerated. Grade 3 toxicities included hand and foot syndrome (11.1%), proteinuria
(4.4%), and renal toxicity (2.2%). Proteinuria (all grades) was correlated with longer PFS (p = 0.017). There was an
inverse relationship between proteinuria and vitamin D levels. VEGF polymorphisms were not associated with patient
outcome.
Conclusion: The XELBEVOCT regimen is active and well tolerated in patients with metastatic WMD-NEN. Proteinuria
correlated with hypovitaminosis D status and was the best predictive factor of treatment efficacy.
Trial registration: Trial registration number NCT01203306.
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Neuroendocrine neoplasms constitute a highly heteroge-
neous spectrum of tumors with a variety of biological and
clinical behaviors. Site-specific classification systems
generally recognize at one end of the spectrum highly ag-
gressive, poorly differentiated neoplasms, termed neu-
roendocrine carcinoma grade 3 of the gastrointestinal
tract and pancreas according to the new World Health
Organization (WHO) classification 2010 [1], and small
and large cell neuroendocrine carcinomas of the lung [2].
At the other end is a highly heterogeneous group of well-
to-moderately differentiated neuroendocrine neoplasms
(WMD-NEN) comprising low-grade (G1) and intermedi-
ate grade (G2) neuroendocrine tumors of the gastrointes-
tinal tract and pancreas [1], typical and atypical carcinoids
of the lung and thymus [2], along with other cancers such
as medullary thyroid carcinoma and pheochromocytoma/
paraganglioma. These neoplasms are relatively rare and,
despite their relatively indolent course, are frequently di-
agnosed in advanced stage [3,4]. Because of their limited
aggressiveness, WMD-NEN are notoriously resistant to
standard chemotherapy and are usually addressed with
biological target therapies [5].
For decades the standard therapy for both functioning
and non-functioning WMD-NEN has been with somato-
statin analogues [6,7]. More recently, target drugs, such as
sunitinib and everolimus, have been shown to be effica-
cious in the management of pancreatic WMD-NEN [8,9].
One of the antiangiogenesis-targeted drugs that can be
added to other types of chemotherapy is bevacizumab, a
monoclonal antibody that blocks vascular endothelial
growth factor (VEGF) by binding to its receptor. In a ran-
domized phase 2 trial, the combination of bevacizumab
and octreotide had a greater efficacy than interferon α2
and octreotide [10]. Common toxicities of bevacizumab
are hypertension and proteinuria; both these adverse
events may lead to premature interruption of drug admi-
nistration. Hypertension, however, has been associated
with drug efficacy in breast cancer and colon cancer pa-
tients [11,12], and proteinuria has been suggested as a po-
tential marker of drug efficacy [13]. In addition, VEGF
polymorphisms have been found to be predictive of hyper-
tension and associated with time to progression in ad-
vanced breast cancer treated with bevacizumab [11].
Hypovitaminosis D is highly prevalent in cancer patients.
It has been reported to increase the risk of cardiovascular
diseases and mortality in such patients [14] and to pro-
mote proteinuria in patients with type 2 diabetes [15]. To
our knowledge, the association of hypovitaminosis D and
bevacizumab-induced proteinuria has never been explored
to date nor has the prognostic role of hypovitaminosis D
been tested in patients with neuroendocrine tumors.
Metronomic administration of chemotherapy inhibits
angiogenesis and vasculogenesis by continuously exposingthe more slowly proliferating tumor endothelial cells to
the damaging action of the cytotoxic therapy [16]. These
requisites make metronomic chemotherapy a suitable ap-
proach in the management of WMD-NEN. In our pre-
vious phase 2 trial, we observed that the combination of
octreotide long-acting release (LAR) therapy 20 mg every
4 weeks plus 5-fluorouracil protracted continuous in-
fusion led to a disease control rate >90% (response +
stabilization) as first-line treatment in the management of
locally advanced or metastatic WMD-NEN [17]. In con-
trast, the response rate obtained with octreotide LAR
alone is generally <5% [6] and the time to progression
reported in the PROMID trial with octreotide LAR 30 mg
every 4 weeks was 14 months [18].
There is a strong rationale for combining metronomic
chemotherapy with antiangiogenic drugs [19]. Prior pre-
clinical metronomic chemotherapy studies have shown
that the combination of antiangiogenic drugs with me-
tronomic chemotherapy can increase antitumor efficacy
compared to either agent alone [19,20]. Capecitabine is an
orally administered third-generation fluoropyrimidine car-
bamate that mimics the tolerability and activity of pro-
tracted intravenous 5-FU infusion [21].
The XELBEVOCT trial, a single-arm multicenter Italian
phase 2 study, was designed to test the activity of the
association of metronomic capecitabine, bevacizumab,
and octreotide in the treatment of advanced/metastatic
WMD-NEN. The primary study aim was the assessment
of activity; the secondary aims were to evaluate toxicity,
time to progression, overall survival, and the relationship
between common toxicities associated with bevacizumab
(hypertension and proteinuria) and drug efficacy. In pre-
defined ancillary studies we also explored the role of cir-
culating VEGF, VEGF polymorphisms, vitamin D status,
and vitamin D metabolism-related polymorphism in pre-
dicting toxicities and treatment efficacy.
Methods
Patients
Eligibility criteria for inclusion in this trial were: histologi-
cally or cytologically proven diagnosis of WMD-NEN;
metastatic or inoperable disease not previously treated
with chemotherapy; age ≥18 years; progressive disease
as documented by Response Evaluation Criteria in Solid
Tumors (RECIST); Eastern Cooperative Oncology Group
(ECOG) performance status 0–2; life expectancy of at
least 12 weeks; measurable and/or evaluable lesions
according to RECIST; adequate bone marrow reserve
(neutrophils ≥1500/mm3 and platelets ≥80,000/mm3);
hemoglobin ≥9.0 g/dl; total bilirubin ≤1.5 times the upper
limit of normal; prothrombin time-international normal-
ized ratio/partial thromboplastin time (PT-INR/PTT) <1.5
times the upper limit of normal; serum creatinine ≤1.5
times the upper limit of normal; potential; ability to
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with a somatostatin analogue and/or radionuclide therapy
were permitted.
Exclusion criteria were: serious non-healing wounds or
ulcers; evidence of bleeding diathesis or coagulopathy;
uncontrolled hypertension; clinically significant car-
diovascular diseases or cerebrovascular accidents; daily
treatment with anticoagulants and high-dose aspirin
(>325 mg/day); use of an investigational drug within
30 days prior to enrollment; known allergy to any of the
components of the study medications; other malignan-
cies diagnosed within the last 5 years, except basal cell
carcinoma or cervical cancer in situ; major surgical pro-
cedures 28 days prior to study treatment start; and preg-
nant or lactating women. This study was first approved
by the Ethic Committee of the Azienda Ospedaliera San
Luigi, Orbassano, Italy. The study was approved by the
local ethics committee of each participating study center.
Written informed consent was obtained from all patients
before starting treatment.
Histology and biochemical analyses
The histological diagnoses performed at each center were
centrally reviewed by two experienced pathologists (MV,
MP). Neuroendocrine phenotype was confirmed by means
of chromogranin A (clone LK2H10, diluted 1:800; Neo-
Markers, Fremont, CA, USA) and synaptophysin (clone
Sy38, diluted 1:100, DakoCytomation, Glostrup, Denmark)
immunostaining. WMD-NEN, irrespective of the primary
tumor site, were characterized by an organoid growth pat-
tern and a mitotic rate <20 in 2 mm2 and the absence of
extensive necrosis. In addition, in all cases in which re-
sidual tumor tissue was available, immunohistochemical
analyses of Ki-67 (clone MIB-1, diluted 1:150, Dako) and
somatostatin receptor type 2A (polyclonal, code SS-800,
diluted 1:3000, BioTrend, Cologne, Germany) were per-
formed. Well-differentiated tumors were defined as those
with a Ki-67 proliferation index ≤2% and/or a mitotic
rate <2; moderately differentiated tumors were defined as
those with a Ki-67 proliferation index between 3% and
20% and/or a mitotic rate between 2 and 20 [1,22]. Plasma
samples were obtained from patients who consented to
having optional blood draws for analysis of VEGF (kit)
and VEGF polymorphisms, circulating vitamin D (25-OH
colecalcipherol) and vitamin D polymorphism. Vitamin D
polymorphism (rs4646536) and VEGF polymorphisms
(rs699947 and rs1570360) were assessed using the ABI
TaqMan allelic discrimination kit by real-time PCR with
standard methodology.
Treatment schedule
Octreotide LAR therapy was administered at a dose of
20 mg every 4 weeks. Capecitabine was administered
orally on a metronomic schedule at a dose of 1000 mgtwice daily without interruption for a maximum of
9 months. Treatment was discontinued earlier in case of
unacceptable toxicity, patient’s withdrawal of consent or
evidence of disease progression. Continuation of capecita-
bine therapy beyond 9 months was permitted according
to the investigator’s discretion. Bevacizumab was given
intravenously at a dose of 5 mg/kg every 2 weeks. Be-
vacizumab treatment was planned to be continued for
9 months in association with capecitabine. Maintenance
bevacizumab treatment until progression or unacceptable
toxicity was prescribed in patients at the individual inves-
tigator’s discretion.
Bevacizumab doses were temporarily discontinued if
proteinuria was >2 g per 24 hours or other grade 3 or 4
toxicities developed. Bevacizumab was permanently with-
drawn if grade 4 hypertension or grade 4 thrombosis
occurred.
The capecitabine dose was modified as follows: delayed
for 1 week if granulocyte counts were <1.5 × 109/L and/or
platelet counts were <100 × 109/L; interrupted until im-
provement to grade 0–1 in the event of hand and foot
syndrome or severe palmar-plantar erythema with blister-
ing and desquamation; discontinued for 1 week in case of
persistent diarrhea, otherwise antidiarrheal agents were
prescribed for grade 1 or 2 diarrhea; stopped for 1 week in
case of grade 2 mucositis; interrupted until recovery in the
event of grade 3 or 4 mucositis, then restarted at a 25% re-
duction in dosage.
Treatment evaluation
Pretreatment and on-study evaluations included: history;
physical examination; laboratory tests; and analysis of
tumor markers (chromogranin A), serum VEGF, VEGF
polymorphism, vitamin D, vitamin D polymorphism. Tu-
mor measurements were made by computed tomography
(CT) scans or magnetic resonance imaging (MRI) at base-
line and every 12 weeks. All radiographic images were
reviewed centrally by an independent radiologist (AMP).
Activity was assessed according to RECIST version 1.0
(CT or MRI) at baseline and every 3 months.
The duration of progression-free survival and overall
survival was measured starting from the date of study
enrollment. Biochemical response was evaluated in pa-
tients with elevated markers at baseline. Response was
defined as a >30% reduction in tumor marker levels or
normalization of the elevated tumor marker. Safety was
assessed according to Common Toxicity Criteria, ver-
sion 3.0.
Statistical analyses
A two-stage Simon design allowing for early stopping was
used [23]. The main end point of the study was the best
change in tumor size at any time point during therapy. In
keeping with a classical two-stage optimal design, a
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able and a response rate > 30% was considered acceptable.
With a two-sided alpha error of 0.05 and a power of
0.90 to detect a true response probability of 30%, 18 pa-
tients were entered in the first stage; if 3 or more pa-
tients responded, the trial entered the second stage and
another 18 patients were recruited. The upper limit of
second-stage rejection was 7 responses observed out of
36 patients enrolled. In order to limit the heterogeneity
of the trial with respect to the sample size, the primary
analysis was performed only in patients with gastroen-
teropancreatic tumors or tumors of unknown primary
origin. Other tumors were recruited for analysis but ana-
lyzed separately. The distribution of PFS and OS was
estimated using the Kaplan-Meier method. The median
PFS and OS in each stratum was calculated with 95%
confidence intervals.
Results
Patient population
The study opened for enrollment in November 2006 and
closed to accrual in April 2009 when 45 consecutive pa-
tients were enrolled at five participating centers. The
primary sites of malignancy were: the pancreas (n = 19);
the intestinal tract (n = 13); the lungs (n = 8); unknown
(n = 4); and a paraganglioma (n = 1). Table 1 reports
patient demographics and characteristics. None of the
patients had received any type of chemotherapy, 19/45
patients (42.2%) had been previously treated with soma-
tostatin analogues, and 23/45 patients (51.1%) with
radionuclide therapy before entering the study.
Chromogranin A serum levels were measured in 42
patients, 34 of which (80.9%) had supranormal values.
The proportion of elevated CgA levels was unevenly dis-
tributed across the 3 patient subgroups.
Clinical activity
Forty-four out of the 45 consecutively enrolled patients
could be assessed for response; the remaining patient
withdrew consent to continue the experimental treatment
after the first cycle and so could not be assessed. Accor-
ding to the intent-to-treat analysis, a partial response was
observed in 8/45 patients (17.8%; 95% CI, 6.4%-28.2%),
stable disease in 29 (64.4%), and disease progression in 8
(17.8%) (Figure 1). The response rate was 22.2% among
the 8/36 patients with gastroenteropancreatic tumors or
with tumors of unknown primary origin. When the pa-
tients were grouped according to the primary cancer site,
a disease response was more frequently observed in those
with pancreatic cancer (5/19, 26.3%) than in those with
non-pancreatic cancer (3/26, 11.5%).
Biochemical response was evaluable in 34 patients:
overall, 18/34 (52.9%) showed a CgA reduction >30%
from baseline; specifically, 6/12 (50.0%) of those withpancreatic cancer, 7/14 (50.0%) with intestinal carcinoids
or cancer of unknown primary origin, and 5/8 (62.5%)
with lung or paraganglioma showed a biochemical re-
sponse, whereas 14/17 patients (82.3%) with a specific
syndrome obtained a symptomatic response.
Progression-free survival and survival
At the last follow-up evaluation in June 2011, 35 (77.8%)
patients showed disease progression and 14 (31.1%) had
died. The median follow-up duration was 38 months.
The median progression-free survival was 14.9 months
(95% CI, 2.4-27.5) for all patients, 14.3 months (95% CI,
3.5-25.0) for those with pancreatic cancer, 14.3 months
(95% CI, 0.0-38.6) for those with intestinal tumor or un-
known primary cancer site, and 18.6 months (95% CI,
7.9-29.2) for those with lung (+ paraganglioma) cancer.
When the patients were grouped according to the re-
sponse obtained, the progression-free survival was 14.9
(95% CI, 2.4-38.6) in those who attained a partial re-
sponse or stable disease and 11.4 (95% CI, 0.0-25) in
those with disease progression. Median overall survival
was not attained in patients with pancreatic cancer or
those with intestinal or unknown primary cancer,
whereas in those with lung neuroendocrine tumors or
paraganglioma the median overall survival was
38 months (95% CI, 35.0-40.1).
Treatment administered and adverse events
Capecitabine treatment was administered for a median
duration of 9 months (range, 1–11). Of the 45 patients
in whom treatment was initiated, 24 (53.3%) completed
the scheduled 9-month treatment and 21 interrupted
earlier due to: progressive disease (n = 11); withdrawal of
consent (n = 5); hand and foot syndrome (n = 2); asthe-
nia (n = 1); venous thrombosis (n = 1); renal impairment
(n = 1); and hepatic chemoembolization (n = 1).
Treatment with metronomic capecitabine and bevaci-
zumab and concomitant octreotide LAR was generally
well tolerated. Most adverse events were mild to moder-
ate in severity (Table 2). The most common adverse
events considered to be related to the study drugs were
nausea/vomiting, diarrhea, hand and foot syndrome,
hypertension, proteinuria, and asthenia. Grade 3 toxi-
cities included: hand and foot syndrome (n = 5,11.1%);
proteinuria (n = 2, 4.4%); and renal toxicity (n = 1, 2.2%).
Octreotide administration was never delayed nor re-
duced. Capecitabine administration was delayed for at
least 1 week in 12 patients (26.7%) and for 2 weeks in 16
patients (35.6%). The most frequent reasons for the de-
layed course were hand and foot syndrome (n = 13), neu-
tropenia (n = 4), and diarrhea (n = 4). The capecitabine
dose was reduced by 25% in 12 patients (26.7%), with
neutropenia (n = 3) and hand and foot syndrome (n = 5)
being the most frequent causes. Bevacizumab was never
Table 1 Patient and clinical characteristics (no. of patients (%))
All (N=45) Pancreatic (N=19) Gastrointestinal intestinal
and unknown origin (N=17)
Others lung and
paraganglioma (N=9)
Sex
Male 32 (71.1) 15 (78.9) 9 (52.9) 8 (88.9)
Female 13 (28.9) 4 (21.1) 8 (47.1) 1 (11.1)
Age (yrs)
Median (range) 52 (28-73)
ECOG performance status
0 36 (80.0) 13 (68.4) 17 (100) 6 (66.7)
1 6 (13.3) 3 (15.8) – 3 (33.3)
2 3 (6.7) 3 (15.8)
Ki67 index
≤2 10 (25.6) 2 (11.8) 5 (33.3) 3 (42.8)
3-20 29 (74.4) 15 (88.2) 15 (66.6) 4 (57.2)
Missing 6 2 2 2
Octreoscan
Positive 43 (95.6) 18 (94.7) 16 (94.1) 9 (100)
Negative 2 (4.4) 1 (5.3) 1 (5.9)
Circulating chromogranin A
Normal 8 3 (17.6) 4 (23.5) 1 (12.5)
Elevated 34 14 (82.4) 13 (76.5) 7 (87.5)
Missing 3 2 – 1
Sites of metastatic disease
Liver 41 (91.1) 18 (94.7) 16 (94.1) 7 (77.8)
Lymph nodes 17 (37.8) 6 (31.4) 8 (47.1) 3 (33.3)
Lung 5 (11.1) 0 (0) – 4 (44.4)
Bone 2 (4.4) 2 (10.5) 1 (5.9) –
Syndrome 17 (37.8) 5 (26.3) 11 (64.7) 1 (11.1)
Diarrhea 10 (22.2) 3 (15.8) 6 (35.3) 1 (11.1)
Hot flashes 7 (15.6) – 6 (35.3) 1 (11.1)
Rash 7 (15.6) – 6 (35.3) 1 (11.1)
Hypoglycemia 1 (2.2) 1 (5.3) – –
Cushing’s syndrome 1 (2.2) 1 (5.3) – –
Previous treatments
Surgery 34 (75.6) 13 (68.4) 14 (82.3) 7 (77.8)
Radiotherapy 2 (4.4) 2 (10.5) – –
Radionuclide therapy with somatostatin analogues 23 (51.1) 10 (43.5) 8 (34.8) 5 (21.7)
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because of renal impairment and deep venous thrombosis,
respectively. Of the 24 patients who completed the 9-
month treatment with bevacizumab, 16 received bevacizu-
mab maintenance and 8 did not for the following reasons:
deep venous thrombosis (n = 2); proteinuria (n = 1); rectal
bleeding (n = 1); and investigator decision (n = 4).Toxicity as a predictive factor of treatment efficacy
Hypertension was not associated with progression-free
survival (p = 0.64) (Figure 2a); however, patients who
experienced proteinuria had a significant gain in progres-
sion-free survival (p = 0.017) (Figure 2b) that was main-
tained after adjusting for bevacizumab treatment duration
(hazard ratio [HR] 0.44; 95% CI, 0.21-0.91; p = 0.028). The
-70
-50
-30
-10
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30
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Figure 1 Waterfall diagram of changes in tumor size in all patients.
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drome and progression-free survival just failed to attain
statistical significance after adjusting for capecitabine treat-
ment duration (HR 0.56; 95% CI, 0.27-1.17; p = 0.13).
VEGF and VEGF polymorphisms as predictors of
bevacizumab toxicity and efficacy
Serum VEGF levels at baseline were available in 36 pa-
tients. Baseline VEGF values, dichotomized at the median
value, failed to be associated with progression-free survival
(HR 1.31; 95% CI, 0.61-2.79).
VEGF polymorphism was analyzed in blood samples
from 28 patients. There was a non significant associa-Table 2 Toxicity
Grade
0 1 2 3
No. of patients (%)
Hematologic
Neutropenia 40 (88.9) 3 (6.7) 2 (4.4)
Anemia 35 (77.8) 5 (11.1) 5 (11.1)
Non hematologic
Nausea/vomiting 29 (64.4) 13 (28.9) 3 (6.7)
Diarrhea 23 (51.1) 17 (37.8) 5 (11.1)
Stomatitis 40 (88.9) 4 (8.9) 1 (2.2)
Hand and foot syndrome 17 (37.8) 12 (26.7) 11 (24.4) 5 (11.1)
Onycholysis 43 (95.6) 2 (4.4)
Hypertension 27 (60.0) 16 (35.6) 2 (4.4)
Proteinuria 20 (44.4) 13 (28.9) 7 (15.6) 2 (4.4)
Hemorrhage 42 (93.7) 3 (6.7)
Thrombosis 43 (95.6) 2 (4.4)
Cardiac 44 (97.8) 1 (2.2)
Fever 34 (75.5) 11 (24.4)
Asthenia 27 (60.0) 15 (33.3) 3 (6.7)tion between rs699947 polymorphism and hypertension:
hypertension was present in7/10 patients (70.0%) with CC
genotype and in 7/18 patients (38.9%) with CA/AA ge-
notype (p = 0.11). No association was found between
rs699947 polymorphism and proteinuria. No association
between rs1570360 polymorphism and either hypertension
or proteinuria was observed. Rs699947 and rs1570360 poly-
morphisms both failed to be associated with progression-
free survival (data not shown).
Serum vitamin D and vitamin D polymorphisms as
predictors of treatment efficacy and toxicity
Serum vitamin D baseline values were available for 36 pa-
tients and circulating vitamin D polymorphism for 28 pa-
tients. Vitamin D status failed to be associated with
hypertension; however, a significant association was found
between proteinuria and the severity of hypovitaminosis D
status: proteinuria was present in 6/8 patients (75.0%) with
serum vitamin D <10 ng/ml, in 10/14 (71.4%) with serum
vitamin D between 10 and 20 ng/ml, and in 5/14 (35.7%)
with serum vitamin D >20 ng/ml (p for trend 0.049).
Vitamin D deficiency (<10 ng/ml) was associated with lon-
ger PFS and approached statistical significance (Figure 3).
Vitamin D polymorphism failed to be associated with
hypertension, proteinuria, and PFS (data not shown).
Discussion
In this study, the combination of octreotide LAR plus
metronomic capecitabine and bevacizumab was active in
the management of patients with metastatic WMD-NEN,
the treatment was well tolerated, and the majority of the
patients completed the treatment plan. As expected,
response was better in patients with pancreatic cancer
than in those with non-pancreatic cancer, and as recently
recognized as the best end point of treatment efficacy in
WMD-NEN [22], progression-free survival was similar in
both subgroups, suggesting that the drug combination
was effective in all subgroups. The similar biochemical re-
sponse observed in all subgroups further supports this
statement. The absence of randomization precluded deter-
mining whether the addition of bevacizumab was syner-
gistic with capecitabine or not.
The response rate obtained in this study was similar to
that observed in our previous trial with octreotide LAR
plus continuous 5-fluorouracil infusion [17], but the pro-
gression-free survival was shorter. The difference between
the two populations and in the inclusion criteria limits
drawing comparison between the two trials. One weakness
of the current trial is the preplanned stop of capecitabine
and bevacizumab at the ninth month. It is unclear
whether that could have influenced the clinical results,
since a significant proportion of patients received bevaci-
zumab until disease progression. Another critical point is
that the efficacious dose rate in the metronomic schedule
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Figure 2 Effect of hypertension (a) and proteinuria (b) on time to progression.
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trial it seems that toxicity is dose-dependent: administration
of 2000 mg/day was associated with the occurrence of G3
hand and foot syndrome in 11% of patients, at variance
with no G3 with 1500 mg/day used in another study [20].
Hypertension, a common side effect of bevacizumab
linked to VEGF inhibition, is associated with a greater effi-
cacy of this monoclonal antibody [11,12], and VEGF poly-
morphisms, which are predictive of bevacizumab-induced
hypertension, are also correlated with the drug’s efficacy[11]. In the present study, neither hypertension nor VEGF
polymorphisms were associated with progression-free sur-
vival; however, proteinuria, a consequence of glomerular
injury due to direct targeting of VEGF [24], was predictive
for longer progression-free survival. To our knowledge,
proteinuria as a predictive factor of bevacizumab efficacy
has been suggested only in a case report to date [13] but
was never demonstrated in a prospective study.
Data from studies in experimental diabetic nephropathy
indicate that vitamin D insufficiency may be involved in
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Figure 3 Influence of hypovitaminosis D on time to progression.
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lation, an inverse association was found between the level
of vitamin D and the prevalence of albuminuria [25].
These observations encouraged us to explore whether
vitamin D status might be associated with the onset of
bevacizumab-induced proteinuria. We found an inverse
relationship between serum vitamin D levels and protein-
uria in the present series. Although association does not
mean causality, this finding suggests that bevacizumab-
induced proteinuria can be effectively treated with ad-
equate vitamin D supplementation. Strong support for this
hypothesis comes from a multicenter prospective rando-
mized clinical trial which showed that paricalcitol admi-
nistered to patients with diabetic nephropathy can lower
albuminuria [26]. While proteinuria was found to be a
marker of bevacizumab efficacy, vitamin D supplementa-
tion may impair the drug’s efficacy. No conclusions can be
drawn from this small patient sample; nonetheless, hy-
povitaminosis D status was associated with a gain in
progression-free survival (approaching statistical sig-
nificance), and this contrasts with previously published
data showing a negative prognostic role of hypovitami-
nosis D [26].
Circulating VEGF levels were found to be prognostic in
patients with advanced WMD-NEN not previously treated
with angiogenesis inhibitors [26]; however, in these patients
receiving a bevacizumab-containing regimen, the marker
failed to be associated with progression-free survival.
Conclusion
In conclusion, XELBEVOCT is an active and well-tolerated
regimen in the management of metastatic WMD-NEN.Proteinuria correlated with hypovitaminosis D status and
was the best predictive factor of treatment efficacy. The
main limitations of this study are its explorative nature and
small population sample size. While the XELBEVOCT
scheme cannot be applied in clinical routine, the regimen’s
activity and efficacy compare favorably with those of cur-
rently available target agents such as sunitinib [8] and
everolimus [9], radionuclide therapy [27] and cytotoxic
therapy [4], particularly with respect to progression-free
survival. The cost of this regimen is similar to that of other
molecular target agents currently used in the management
of neuroendocrine tumors. In our opinion, the XELBE-
VOCT regimen merits further testing in prospective phase
3 trials.
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